PDF icon PDF herunterladen
J Wrist Surg 2023; 12(04): 324-330
DOI: 10.1055/s-0042-1757766
Scientific Article

Pyrocardan Implant Arthroplasty for Carpometacarpal Osteoarthritis of the Thumb: A Comparative Study with a Historical Control Group

Rasmus Wejnold Jørgensen 
1   Department of Orthopaedic Surgery, Herlev-Gentofte University Hospital of Copenhagen, Hand Clinic, Copenhagen, Denmark
,
Kiran Annette Anderson
2   Department of Orthopaedics, Herlev-Gentofte University Hospital of Copenhagen, Hand Clinic, Copenhagen, Denmark
,
Anders Odgaard
3   Department of Orthopaedic Surgery, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
,
Claus Hjorth Jensen
2   Department of Orthopaedics, Herlev-Gentofte University Hospital of Copenhagen, Hand Clinic, Copenhagen, Denmark
› Institutsangaben
Funding The author(s) received no financial support for the research, authorship, and/or publication of this article.
› Weitere Informationen
   Lizenzen und Reprints
Preview

Abstract

Background New and improved surgical techniques are warranted to treat osteoarthritis of the thumb carpometacarpal joint (CMC-1). The Pyrocardan implant yields striking results but only few series exist, making the evidence scarce.

Purpose The aim of this study was to conduct a prospective series using the Pyrocardan implant.

Methods We compared the outcomes to a matched historical control group of patients operated on with ligament reconstruction and tendon interposition. The hypothesis was that the Pyrocardan implant would yield better patient-reported outcomes as well as the procedure would be safe and effective in relieving symptoms of CMC-1 osteoarthritis. In total, 30 patients were included in the prospective series. These 30 patients were compared, in a 1:3 design, to a matched historical group.

Results Results were promising with visual analogue scale scores of 0.7 (rest) and 2.1 (function), key-pinch score of 5.1 kg, and shortened Disability of the Arm, Shoulder, and Hand score of 14.3 after 1 year when using the Pyrocardan implant. The revision rate was 10%. We found no evidence of subsidence of the thumb. We found no differences in patient-reported outcomes between the two groups.

Conclusions In conclusion, the Pyrocardan implant is a viable option in the treatment of CMC-1 osteoarthritis but with a significant revision rate. When comparing the Pyrocardan implant to a historical control group, we failed to find any differences in patient-reported outcomes.

Level of Evidence IV – case series.

Keywords

Pyrocarbon - Quick-DASH - patient-reported outcome - thumb carpometacarpal joint osteoarthritis

Informed Consent

Written informed consent was obtained from all patients before the study.


Ethical Approval

The study was conducted as a medical technological evaluation. The regional ethical committee reviewed the study and decided it did not need approval (H-19086573).


Trial Registration

The Danish Data Protection Agency: jr. nr. (P-2020–129).


Author Contributions

C.H.J. and R.W.J. conceived the study. C.H.J. gained approval for the study. K.A.A. did some of the procedures, collected data, and aided in the writing of the manuscript. R.W.J. conducted the study, collected data, did the statistical analysis, wrote the manuscript, and submitted the manuscript. A.O supervised the project and did statistical aid.




Publikationsverlauf

Eingereicht: 31. Januar 2022

Angenommen: 05. September 2022

Artikel online veröffentlicht:
28. November 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA